PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced that new research on its investigational immunotherapy, INO-3107, will be presented at the American Association for Cancer Research – Immuno-Oncology conference from February 23-26, 2025. The findings could represent a significant advancement in the treatment of recurrent respiratory papillomatosis (RRP).
The poster, titled “Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107,” will provide insights into the immunological activity of INO-3107. This therapy has demonstrated potential to elicit a strong T-cell response, effectively targeting HPV-6 in patients with RRP—a condition characterized by benign yet recurring growths in the respiratory tract caused by this virus.
The presentation highlights the capability of INO-3107 to address unmet needs for those suffering from this challenging disease. The therapy’s mechanism aims to harness the power of immunotherapy, focusing on inducing robust immune responses to eliminate disease-causing cells while potentially offering long-term benefits for patients.
The abstract will be available on INOVIO’s website following the conference, reflecting the company’s dedication to transparency and knowledge-sharing within the scientific community.
Looking ahead, INOVIO states that it remains at the forefront of immunotherapy innovation, committed to advancing solutions that address some of the most pressing challenges in medicine. The progress of INO-3107 reinforces INOVIO’s mission to improve patients’ lives through cutting-edge science and targeted therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.